Neptune Technologies & Bioressources Inc. Subsidiary Acasti Pharma Inc. Reports Superior Effect of Drug Candidate CaPre(TM) Over
2010年11月4日 - 8:00PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX.V.NTB) subsidiary Acasti Pharma Inc. ("Acasti")
reports preclinical results showing that its leading drug candidate
CaPre™, performed significantly better than the currently marketed
drug, Lovaza®, at managing impaired glucose tolerance (IGT) a
serious pre-diabetic state associated with increased risk of
diabetes and heart disease.
The results of the present preclinical study indicate that
CaPre™ significantly improved the established IGT found in ZDF rats
(compared to normal healthy Sprague-Dawley rats), as compared to
Lovaza® after one and three months of oral daily administration.
Daily treatment with 0.5g CaPre™ reduced IGT by 21% after only one
month and further reduced IGT by up to 35% after three months
compared to Lovaza® which achieved a 5% reduction after three
months of treatment.
"These results clearly demonstrate that CaPre™ not only has the
ability to modulate favorably blood lipids, but also the ability to
potentially lower the detrimental effects of impaired glucose
tolerance associated with increased morbidity in cardiometabolic
patients, When compared to Lovaza®, our data suggests for CaPre™ a
more complete overall effect at a significantly lower and easier to
tolerate daily dose" said Dr. Farhad Amiri, Associate-Director,
Preclinical Studies.
"These results along with previously reported beneficial
lipid-management effects of CaPreÔ, repeatedly shown to
significantly reduce triglycerides and LDL ("bad cholesterol")
while increasing HDL ("good cholesterol"), suggest that Acasti's
prescription drug candidate CaPre™ potentially offers a more
complete lipid management in cardiometabolic patients that are
characterized by having both dyslipidema and impaired glucose
tolerance than currently available options", said Dr. Tina
Sampalis, President of Acasti.
Adult male rats of an established model of severe dyslipidemia
and type 2 diabetes, received either 0.5g CaPre™ or 4g Lovaza® in
daily human equivalent dosing (HED) over 12 consecutive
weeks. At the end of each month, rats were fasted for 12 hours
and underwent an Oral Glucose Tolerance Test (OGTT), a routine test
for diabetic patients. Briefly, blood glucose levels were
measured after 12 hours (overnight) of fasting and then every 30
minutes for 3 hours after ingesting a glucose load.
Lovaza® is the only FDA approved prescription fish oil solely
indicated for the treatment of severe hypertriglyceridemia (very
high triglycerides >500mg/dl). According to market research firm
IMS Health, global sales of Lovaza® topped $1 billion in 2009, with
$758 million of those sales originating in the U.S. GlaxoSmithKline
PLC (LSE/NYSE:GSK) acquired the USA rights to Lovaza® by its
acquisition of Reliant Pharmaceuticals Inc., in 2007 for $1.65
billion.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide. Neptune is the mother company of Acasti and
NeuroBioPharm.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
CEOcast
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
1 (888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024